Advanced Search
Display options
Filter resources
Text Availability
Article type
Publication date
Species
Language
Sex
Age
Showing 1 to 9 of 9 entries
Sorted by: Best Match Show Resources per page
Emerging interventions for elderly patients—The promise of regenerative medicine

Stem career interventions

Roubenoff R.
GSID: gwQRknP0dYgJ
RR Miller, R Roubenoff - Clinical Pharmacology & Therapeutics, 2019 - Wiley Online Library

The impressive increase in lifespan that occurred in the 20th century has driven a boom in age‐associated degeneration resulting from senescence. Geriatric syndromes, such as sarcopenia and frailty, do not fall neatly into classical medical definitions of disease because...

Cite
Miller, R. R., & Roubenoff, R. (2019). Emerging interventions for elderly patients—The promise of regenerative medicine. Clinical Pharmacology & Therapeutics, 105(1), 53-60.‏
Miller, Ram R., and Ronenn Roubenoff. "Emerging interventions for elderly patients—The promise of regenerative medicine." Clinical Pharmacology & Therapeutics 105.1 (2019): 53-60.‏
Copy Download .nbib Format: MLA
Nutrition treatment for HIV wasting: a prescription for food as Medicine.

Nutrition in clinical practice : official publication of the American Society for Parenteral and Enteral Nutrition

McDermott AY, Shevitz A, Must A, Harris S, Roubenoff R, Gorbach S.
PMID: 16215024
Nutr Clin Pract. 2003 Feb;18(1):86-94. doi: 10.1177/011542650301800186.

BACKGROUND: The optimal nutrition approach for the promotion of weight gain in HIV-infected adults with wasting remains unclear. Previous dietary interventions report minimal success and provide inadequate information regarding the counseling approach, contact time, session format, and issues addressed...

Cite
McDermott AY, Shevitz A, Must A, et al. Nutrition treatment for HIV wasting: a prescription for food as Medicine. Nutr Clin Pract. 2003;18(1):86-94doi: 10.1177/011542650301800186.
McDermott, A. Y., Shevitz, A., Must, A., Harris, S., Roubenoff, R., & Gorbach, S. (2003). Nutrition treatment for HIV wasting: a prescription for food as Medicine. Nutrition in clinical practice : official publication of the American Society for Parenteral and Enteral Nutrition, 18(1), 86-94. https://doi.org/10.1177/011542650301800186
McDermott, Ann Yelmokas, et al. "Nutrition treatment for HIV wasting: a prescription for food as Medicine." Nutrition in clinical practice : official publication of the American Society for Parenteral and Enteral Nutrition vol. 18,1 (2003): 86-94. doi: https://doi.org/10.1177/011542650301800186
McDermott AY, Shevitz A, Must A, Harris S, Roubenoff R, Gorbach S. Nutrition treatment for HIV wasting: a prescription for food as Medicine. Nutr Clin Pract. 2003 Feb;18(1):86-94. doi: 10.1177/011542650301800186. PMID: 16215024.
Copy Download .nbib Format: NLM
Validity, reliability and responsiveness to change of the French version of the drooling impact scale.

Disability and rehabilitation

Bard-Pondarré R, Roumenoff F, Julien C, Grguric G, Porte M, Boulay C, Bourg V, Chaléat-Valayer E.
PMID: 32552097
Disabil Rehabil. 2020 Jun 17;1-7. doi: 10.1080/09638288.2020.1777471. Epub 2020 Jun 17.

No abstract available.

Cite
Bard-Pondarré R, Roumenoff F, Julien C, et al. Validity, reliability and responsiveness to change of the French version of the drooling impact scale. Disabil Rehabil. 2020;1-7doi: 10.1080/09638288.2020.1777471.
Bard-Pondarré, R., Roumenoff, F., Julien, C., Grguric, G., Porte, M., Boulay, C., Bourg, V., & Chaléat-Valayer, E. (2020). Validity, reliability and responsiveness to change of the French version of the drooling impact scale. Disability and rehabilitation, 1-7. https://doi.org/10.1080/09638288.2020.1777471
Bard-Pondarré, Rachel, et al. "Validity, reliability and responsiveness to change of the French version of the drooling impact scale." Disability and rehabilitation vol. (2020): 1-7. doi: https://doi.org/10.1080/09638288.2020.1777471
Bard-Pondarré R, Roumenoff F, Julien C, Grguric G, Porte M, Boulay C, Bourg V, Chaléat-Valayer E. Validity, reliability and responsiveness to change of the French version of the drooling impact scale. Disabil Rehabil. 2020 Jun 17;1-7. doi: 10.1080/09638288.2020.1777471. Epub 2020 Jun 17. PMID: 32552097.
Copy Download .nbib Format: NLM
A Roadmap to Inform Development, Validation and Approval of Digital Mobility Outcomes: The Mobilise-D Approach.

Digital biomarkers

Rochester L, Mazzà C, Mueller A, Caulfield B, McCarthy M, Becker C, Miller R, Piraino P, Viceconti M, Dartee WP, Garcia-Aymerich J, Aydemir AA, Vereijken B, Arnera V, Ammour N, Jackson M, Hache T, Roubenoff R.
PMID: 33442578
Digit Biomark. 2020 Nov 26;4:13-27. doi: 10.1159/000512513. eCollection 2020.

Health care has had to adapt rapidly to COVID-19, and this in turn has highlighted a pressing need for tools to facilitate remote visits and monitoring. Digital health technology, including body-worn devices, offers a solution using digital outcomes to...

Cite
Rochester L, Mazzà C, Mueller A, et al. A Roadmap to Inform Development, Validation and Approval of Digital Mobility Outcomes: The Mobilise-D Approach. Digit Biomark. 2020;4:13-27doi: 10.1159/000512513.
Rochester, L., Mazzà, C., Mueller, A., Caulfield, B., McCarthy, M., Becker, C., Miller, R., Piraino, P., Viceconti, M., Dartee, W. P., Garcia-Aymerich, J., Aydemir, A. A., Vereijken, B., Arnera, V., Ammour, N., Jackson, M., Hache, T., & Roubenoff, R. (2020). A Roadmap to Inform Development, Validation and Approval of Digital Mobility Outcomes: The Mobilise-D Approach. Digital biomarkers, 413-27. https://doi.org/10.1159/000512513
Rochester, Lynn, et al. "A Roadmap to Inform Development, Validation and Approval of Digital Mobility Outcomes: The Mobilise-D Approach." Digital biomarkers vol. 4 (2020): 13-27. doi: https://doi.org/10.1159/000512513
Rochester L, Mazzà C, Mueller A, Caulfield B, McCarthy M, Becker C, Miller R, Piraino P, Viceconti M, Dartee WP, Garcia-Aymerich J, Aydemir AA, Vereijken B, Arnera V, Ammour N, Jackson M, Hache T, Roubenoff R. A Roadmap to Inform Development, Validation and Approval of Digital Mobility Outcomes: The Mobilise-D Approach. Digit Biomark. 2020 Nov 26;4:13-27. doi: 10.1159/000512513. eCollection 2020. PMID: 33442578; PMCID: PMC7768123.
Copy Download .nbib Format: NLM
Biomarkers of sarcopenia in clinical trials-recommendations from the International Working Group on Sarcopenia.

Journal of cachexia, sarcopenia and muscle

Cesari M, Fielding RA, Pahor M, Goodpaster B, Hellerstein M, van Kan GA, Anker SD, Rutkove S, Vrijbloed JW, Isaac M, Rolland Y, M'rini C, Aubertin-Leheudre M, Cedarbaum JM, Zamboni M, Sieber CC, Laurent D, Evans WJ, Roubenoff R, Morley JE, Vellas B.
PMID: 22865205
J Cachexia Sarcopenia Muscle. 2012 Sep;3(3):181-90. doi: 10.1007/s13539-012-0078-2. Epub 2012 Aug 03.

Sarcopenia, the age-related skeletal muscle decline, is associated with relevant clinical and socioeconomic negative outcomes in older persons. The study of this phenomenon and the development of preventive/therapeutic strategies represent public health priorities. The present document reports the results...

Cite
Cesari M, Fielding RA, Pahor M, et al. Biomarkers of sarcopenia in clinical trials-recommendations from the International Working Group on Sarcopenia. J Cachexia Sarcopenia Muscle. 2012;3(3):181-90doi: 10.1007/s13539-012-0078-2.
Cesari, M., Fielding, R. A., Pahor, M., Goodpaster, B., Hellerstein, M., van Kan, G. A., Anker, S. D., Rutkove, S., Vrijbloed, J. W., Isaac, M., Rolland, Y., M'rini, C., Aubertin-Leheudre, M., Cedarbaum, J. M., Zamboni, M., Sieber, C. C., Laurent, D., Evans, W. J., Roubenoff, R., Morley, J. E., Vellas, B. (2012). Biomarkers of sarcopenia in clinical trials-recommendations from the International Working Group on Sarcopenia. Journal of cachexia, sarcopenia and muscle, 3(3), 181-90. https://doi.org/10.1007/s13539-012-0078-2
Cesari, Matteo, et al. "Biomarkers of sarcopenia in clinical trials-recommendations from the International Working Group on Sarcopenia." Journal of cachexia, sarcopenia and muscle vol. 3,3 (2012): 181-90. doi: https://doi.org/10.1007/s13539-012-0078-2
Cesari M, Fielding RA, Pahor M, Goodpaster B, Hellerstein M, van Kan GA, Anker SD, Rutkove S, Vrijbloed JW, Isaac M, Rolland Y, M'rini C, Aubertin-Leheudre M, Cedarbaum JM, Zamboni M, Sieber CC, Laurent D, Evans WJ, Roubenoff R, Morley JE, Vellas B. Biomarkers of sarcopenia in clinical trials-recommendations from the International Working Group on Sarcopenia. J Cachexia Sarcopenia Muscle. 2012 Sep;3(3):181-90. doi: 10.1007/s13539-012-0078-2. Epub 2012 Aug 03. PMID: 22865205; PMCID: PMC3424187.
Copy Download .nbib Format: NLM
PHARMACOLOGICAL INTERVENTIONS IN FRAILTY AND SARCOPENIA: REPORT BY THE INTERNATIONAL CONFERENCE ON FRAILTY AND SARCOPENIA RESEARCH TASK FORCE.

The Journal of frailty & aging

Cesari M, Fielding R, Bénichou O, Bernabei R, Bhasin S, Guralnik JM, Jette A, Landi F, Pahor M, Rodriguez-Manas L, Rolland Y, Roubenoff R, Sinclair AJ, Studenski S, Travison T, Vellas B.
PMID: 26366378
J Frailty Aging. 2015;4(3):114-120. doi: 10.14283/jfa.2015.64.

Sarcopenia and frailty often co-exist and both have physical function impairment as a core component. Yet despite the urgency of the problem, the development of pharmaceutical therapies for sarcopenia and frailty has lagged, in part because of the lack...

Cite
Cesari M, Fielding R, Bénichou O, et al. PHARMACOLOGICAL INTERVENTIONS IN FRAILTY AND SARCOPENIA: REPORT BY THE INTERNATIONAL CONFERENCE ON FRAILTY AND SARCOPENIA RESEARCH TASK FORCE. J Frailty Aging. 2015;4(3):114-120doi: 10.14283/jfa.2015.64.
Cesari, M., Fielding, R., Bénichou, O., Bernabei, R., Bhasin, S., Guralnik, J. M., Jette, A., Landi, F., Pahor, M., Rodriguez-Manas, L., Rolland, Y., Roubenoff, R., Sinclair, A. J., Studenski, S., Travison, T., & Vellas, B. (2015). PHARMACOLOGICAL INTERVENTIONS IN FRAILTY AND SARCOPENIA: REPORT BY THE INTERNATIONAL CONFERENCE ON FRAILTY AND SARCOPENIA RESEARCH TASK FORCE. The Journal of frailty & aging, 4(3), 114-120. https://doi.org/10.14283/jfa.2015.64
Cesari, M, et al. "PHARMACOLOGICAL INTERVENTIONS IN FRAILTY AND SARCOPENIA: REPORT BY THE INTERNATIONAL CONFERENCE ON FRAILTY AND SARCOPENIA RESEARCH TASK FORCE." The Journal of frailty & aging vol. 4,3 (2015): 114-120. doi: https://doi.org/10.14283/jfa.2015.64
Cesari M, Fielding R, Bénichou O, Bernabei R, Bhasin S, Guralnik JM, Jette A, Landi F, Pahor M, Rodriguez-Manas L, Rolland Y, Roubenoff R, Sinclair AJ, Studenski S, Travison T, Vellas B. PHARMACOLOGICAL INTERVENTIONS IN FRAILTY AND SARCOPENIA: REPORT BY THE INTERNATIONAL CONFERENCE ON FRAILTY AND SARCOPENIA RESEARCH TASK FORCE. J Frailty Aging. 2015;4(3):114-120. doi: 10.14283/jfa.2015.64. PMID: 26366378; PMCID: PMC4563815.
Copy Download .nbib Format: NLM
Colony-Stimulating Factor-1 Antibody Lacnotuzumab in a Phase 1 Healthy Volunteer Study and Mechanistic Investigation of Safety Outcomes.

The Journal of pharmacology and experimental therapeutics

Pognan F, Couttet P, Demin I, Jaitner B, Pang Y, Roubenoff R, Sutter E, Timsit Y, Valentin MA, Vogel B, Woerly G, Wolf A, Schramm U.
PMID: 30894455
J Pharmacol Exp Ther. 2019 Jun;369(3):428-442. doi: 10.1124/jpet.118.254128. Epub 2019 Mar 20.

The colony-stimulating factor-1 (CSF-1) receptor pathway has been implicated in a variety of diseases, and CSF-1-dependent mechanisms are also involved in bloodborne protein clearance. Lacnotuzumab is a novel, high-affinity, humanized, anti-CSF-1 monoclonal antibody that prevents CSF-1-mediated receptor activation. This...

Cite
Pognan F, Couttet P, Demin I, et al. Colony-Stimulating Factor-1 Antibody Lacnotuzumab in a Phase 1 Healthy Volunteer Study and Mechanistic Investigation of Safety Outcomes. J Pharmacol Exp Ther. 2019;369(3):428-442doi: 10.1124/jpet.118.254128.
Pognan, F., Couttet, P., Demin, I., Jaitner, B., Pang, Y., Roubenoff, R., Sutter, E., Timsit, Y., Valentin, M. A., Vogel, B., Woerly, G., Wolf, A., & Schramm, U. (2019). Colony-Stimulating Factor-1 Antibody Lacnotuzumab in a Phase 1 Healthy Volunteer Study and Mechanistic Investigation of Safety Outcomes. The Journal of pharmacology and experimental therapeutics, 369(3), 428-442. https://doi.org/10.1124/jpet.118.254128
Pognan, Francois, et al. "Colony-Stimulating Factor-1 Antibody Lacnotuzumab in a Phase 1 Healthy Volunteer Study and Mechanistic Investigation of Safety Outcomes." The Journal of pharmacology and experimental therapeutics vol. 369,3 (2019): 428-442. doi: https://doi.org/10.1124/jpet.118.254128
Pognan F, Couttet P, Demin I, Jaitner B, Pang Y, Roubenoff R, Sutter E, Timsit Y, Valentin MA, Vogel B, Woerly G, Wolf A, Schramm U. Colony-Stimulating Factor-1 Antibody Lacnotuzumab in a Phase 1 Healthy Volunteer Study and Mechanistic Investigation of Safety Outcomes. J Pharmacol Exp Ther. 2019 Jun;369(3):428-442. doi: 10.1124/jpet.118.254128. Epub 2019 Mar 20. PMID: 30894455.
Copy Download .nbib Format: NLM
The "Sarcopenia and Physical fRailty IN older people: multi-componenT Treatment strategies" (SPRINTT) project: advancing the care of physically frail and sarcopenic older people.

Aging clinical and experimental research

Bernabei R, Mariotti L, Bordes P, Roubenoff R.
PMID: 28144913
Aging Clin Exp Res. 2017 Feb;29(1):1-2. doi: 10.1007/s40520-016-0707-2. Epub 2017 Jan 31.

No abstract available.

Cite
Bernabei R, Mariotti L, Bordes P, et al. The "Sarcopenia and Physical fRailty IN older people: multi-componenT Treatment strategies" (SPRINTT) project: advancing the care of physically frail and sarcopenic older people. Aging Clin Exp Res. 2017;29(1):1-2doi: 10.1007/s40520-016-0707-2.
Bernabei, R., Mariotti, L., Bordes, P., & Roubenoff, R. (2017). The "Sarcopenia and Physical fRailty IN older people: multi-componenT Treatment strategies" (SPRINTT) project: advancing the care of physically frail and sarcopenic older people. Aging clinical and experimental research, 29(1), 1-2. https://doi.org/10.1007/s40520-016-0707-2
Bernabei, Roberto, et al. "The "Sarcopenia and Physical fRailty IN older people: multi-componenT Treatment strategies" (SPRINTT) project: advancing the care of physically frail and sarcopenic older people." Aging clinical and experimental research vol. 29,1 (2017): 1-2. doi: https://doi.org/10.1007/s40520-016-0707-2
Bernabei R, Mariotti L, Bordes P, Roubenoff R. The "Sarcopenia and Physical fRailty IN older people: multi-componenT Treatment strategies" (SPRINTT) project: advancing the care of physically frail and sarcopenic older people. Aging Clin Exp Res. 2017 Feb;29(1):1-2. doi: 10.1007/s40520-016-0707-2. Epub 2017 Jan 31. PMID: 28144913.
Copy Download .nbib Format: NLM
Urinary 8-hydroxy-2'-deoxyguanosine (8-OHdG) as a marker of oxidative stress in rheumatoid arthritis and aging: effect of progressive resistance training.

The Journal of nutritional biochemistry

Rall LC, Roubenoff R, Meydani SN, Han SN, Meydani M.
PMID: 11137896
J Nutr Biochem. 2000 Nov;11(11):581-584. doi: 10.1016/s0955-2863(00)00123-6.

Urinary 8-hydroxy-2'-deoxyguanosine (8-OHdG), as a measure of oxidative stress, was measured before and after 12 weeks of progressive resistance strength training in 8 healthy elderly (65-80 yr) and eight healthy young (22-30 yr) men and women, and in eight...

Cite
Rall LC, Roubenoff R, Meydani SN, et al. Urinary 8-hydroxy-2'-deoxyguanosine (8-OHdG) as a marker of oxidative stress in rheumatoid arthritis and aging: effect of progressive resistance training. J Nutr Biochem. 2000;11(11):581-584doi: 10.1016/s0955-2863(00)00123-6.
Rall, L. C., Roubenoff, R., Meydani, S. N., Han, S. N., & Meydani, M. (2000). Urinary 8-hydroxy-2'-deoxyguanosine (8-OHdG) as a marker of oxidative stress in rheumatoid arthritis and aging: effect of progressive resistance training. The Journal of nutritional biochemistry, 11(11), 581-584. https://doi.org/10.1016/s0955-2863(00)00123-6
Rall, et al. "Urinary 8-hydroxy-2'-deoxyguanosine (8-OHdG) as a marker of oxidative stress in rheumatoid arthritis and aging: effect of progressive resistance training." The Journal of nutritional biochemistry vol. 11,11 (2000): 581-584. doi: https://doi.org/10.1016/s0955-2863(00)00123-6
Rall LC, Roubenoff R, Meydani SN, Han SN, Meydani M. Urinary 8-hydroxy-2'-deoxyguanosine (8-OHdG) as a marker of oxidative stress in rheumatoid arthritis and aging: effect of progressive resistance training. J Nutr Biochem. 2000 Nov;11(11):581-584. doi: 10.1016/s0955-2863(00)00123-6. PMID: 11137896.
Copy Download .nbib Format: NLM
Showing 1 to 9 of 9 entries